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Acancerstemcellhasbeendeﬁnedasacellwithinatumorthatpossessesthecapacitytoself-renewandtocausetheheterogeneous
lineages of cancer cells that comprise the tumor. These tumor-forming cells could hypothetically originate from stem, progenitor,
or diﬀerentiated cells. Previously, we have shown that breast cancer cells with low metastatic potential can be induced into a
reversible state of dormancy by farnesyl transferase inhibitors (FTIs). Dormancy was induced by changes in RhoA and RhoC
GTPases. Speciﬁcally, RhoA was found to be hypoactivated while RhoC was hyperactivated. In the current study we demonstrate
that these dormant cells also express certain known stem cell markers such as aldehyde dehydrogenase I (ALDHI) and cluster of
diﬀerentiation 44 (CD44).We also show that autophagy markers Atg5, Atg12,and LC3-B areexpressed in thesedormant stem cell-
like breast cancer cells. Inhibiting autophagy by inhibitor 3-methyladenine (3-MA) blocked the process of autophagy reversing the
dormant phenotype. Further, we show that c-jun NH2 terminal kinase (JNK/SAPK) is upregulated in these dormant stem cell-like
breast cancer cells and is responsible for increasing autophagy.
1.Introduction
Metastatic breast cancer is the leading cause of cancer death
in women in the United States [1]. Improvements in the
understandingofthemolecularunderpinningsofbreastcan-
cer,coupledwithimprovementsinmultimodalitytreatments
have greatly improved the overall survival of breast cancer
patients [1–3]. However, a subset of women who appear to
have been “cured” of their cancer recur years, if not decades,
later [4]. These recurrences are due to the presence of latent
or dormant tumor cells [5–7]. Often dormant tumor cells,
termeddisseminatedtumorcells,canbedetectedinthebone
marrow of women in remission of their cancer [8, 9].
The mechanisms of tumor cell dormancy are currently
notunderstood.Ourlaboratoryhasdemonstratedthattreat-
ment of breast tumor cells with farnesyl transferase inhib-
itors (FTIs) leads to a phenotype reminiscent of dormancy
[10, 11]. Further, FTI treatment of the MCF-7 cell line leads
to profound changes in Rho GTPase activation [10]. Specif-
ically, RhoA GTPase becomes hypoactivated while RhoC
GTPase becomes hyperactivated. These changes lead to radi-
cal changes in the cell cytoskeleton and cellular morphology.
Decreased levels of RhoA activation are also consistent with
an accepted in vitro model of breast cancer cell dormancy
[12–14].
Similar to what is observed for the in vitro model [12,
13], FTI-induced dormancy is reversible. Upon FTI with-
drawal cells grow normally after exiting from nearly two
weeks of dormancy [10]. FTI-treated cells appear to have
minimal metabolic activity, yet remain viable. Thus, we be-
lieve that under these conditions the cells have undergone
the process of autophagy. Autophagy is the process where
a cell degrades organelles such as mitochondria to expend
less energy avoiding apoptosis [15]. Autophagy is regulated
through the extracellular matrix and is suggested to be re-
quired for dormancy [16–18]. In addition, activation of the
c-jun NH2 terminal kinase (JNK/SAPK) signaling pathway
occurs during autophagy [19, 20]. In our previous study
we demonstrated that increased RhoC GTPase activation2 Bone Marrow Research
during FTI treatment increased JNK/SAPK signaling leading
to breast tumor cell dormancy [10].
It has been suggested that breast cancer cells with stem
cell-likepropertiesareresponsibleformetastaticspread[21].
These cells express stem cell markers such as aldehyde de-
hydrogenase I (ALDHI) and cluster of diﬀerentiation 44
(CD44) as well as RhoC GTPase [22–24]. Furthermore, it is
suggested that dormant breast cancer cells are of cancer
stem cell origin [21, 25]. The stem cell origin of dormant
cells would help explain how outgrowth of the dormant cell
can lead to rapid tumor growth and dissemination. Recent
reports suggest that the MCF-7 cell line is comprised of a
large proportion of cells displaying stem cell-like properties
[26, 27]. MCF-7 cells readily undergo dormancy in diﬀerent
in vitro and in vivo models including FTI-treatment [10].
In the current study we hypothesized that the breast tu-
mor cells aﬀected by FTI treatment would express breast
tumor stem cell markers. Further, we hypothesized that FTI-
induced changes in Rho GTPase activation leading to in-
creased JNK/SAPK signaling would induce autophagy in
these cells. Here we show that cells aﬀected by FTI treatment
express breast cancer stem cell markers ALDH1 and CD44.
In addition, these cells appear to be undergoing autophagy
through a RhoC GTPase- and JNK/SAPK-dependent signal-
ing pathway. These data are the ﬁrst to demonstrate the role
of stem cells and autophagy in FTI-induced breast tumor cell
dormancy and may have implication for future therapeutic
uses of FTIs.
2.MaterialsandMethods
2.1. Cell Culture, FTI Treatment, and Transfections. MCF-
7 breast cancer cell line was obtained from American Type
Culture Collection (Manassas, VA) and maintained at 37◦C
with 5% CO2 levels in DMEM (Mediatech, VA)/10%
FBS (Altanta Biologicals, GA)/1% Penicillin-Streptomycin
(Mediatech, VA). Cell line was validated for authenticity
by the Johns Hopkins Genetics Resource Core Facility. FTI
L-744,832 was kindly provided by Dr. George Prendergast
(Lankenau Institute for Medical Research) and treatment for
dormancy was performed as previously described [10].
Transfections were performed using constitutively active
and dominant negative mutant clones of RhoC, G14V, and
T19N, respectively (Missouri S&T cDNA Resource Center).
FugeneHD (Roche) was used as the transfection reagent
and transfection performed according to the manufacturers
instructions.
For cells treated with the JNK inhibitor SP600125 (EMD
Biosciences, Gibbstown, NJ): MCF-7 cells were plated at a
clonogenic density of 10,000 cells per well in six-well plates
and treated with 25μMo fF T If o r2 4 h .2 5 μM SP600125,
pharmacological inhibitor of JNK, was added in each well in
2mL of medium along with 0.25% sterile dimethyl sulfoxide
(DMSO). As control, 0.25% DMSO in 2mL of medium was
added to the FTI-alone treated cells. 3-Methyladenine (3-
MA)(Calbiochem,CA)wasdissolvedindimethylformamide
(DMF) and added to cells originally plated at a clonogenic
density of 10,000 cells per well in 6-well plates after dor-
mancy was induced by treating them with 25μMF T If o r
24h. The working concentration of 3-MA was 5mM.
2.2. Immunoﬂuorescence. Dormancy was induced for 72h by
FTI treatment, the cells ﬁxed with 4% paraformaldehyde,
extracted in 0.1% Triton-X-100 in PBS, blocked with block-
ing buﬀer containing 3% Bovine Serum Albumin (BSA) plus
10% normal rabbit or goat serum, respectively. Cells were
thenincubatedwitheitheranti-ALDH1mouseprimaryanti-
body (1:1000) (BD Transduction Labs) or anti-CD44 rabbit
primary antibody (1:1000) (Strategic Diagnostics, Newark,
DE).ForALDH1staining,AlexaFluor568rabbitanti-mouse
secondary antibody (Molecular Probes, Invitrogen) was used
while Alexa Fluor 488 goat anti-rabbit secondary antibody
(Molecular Probes, Invitrogen) was used for CD44 staining.
Draq5 (Biostatus Limited, UK) was used to stain the nuclei
in both cases. IgG controls were used in both cases as neg-
ative controls. Immunoﬂuorescence was performed on a
Ziess LSM5 High-speed Live confocal microscope housed in
Delaware Biotechnology Institute.
2.3. Western Blotting. Western blotting was performed as
previously described [10]. Brieﬂy, proteins were harvested
using RIPA buﬀer containing protease inhibitor cocktail.
Lysates were separated by SDS-PAGE on a 4–20% (w/v) gel
(Biorad, Hercules, CA) transferred to nitrocellulose, blocked
and probed with a monoclonal antibodies for phosphoryl-
ated and total JNK (Cell Signaling, Beverly, MA) and auto-
phagy marker LC3B and other genes using the autophagy
sampler kit (Cell Signaling, MA). After incubation with a
goat anti-rabbit-horseradish peroxidase (HRP) (Cell Signal-
ing,MA)immunoblotsweredevelopedwithECL,exposedto
Hyperﬁlm (Amersham, Piscataway, NJ) and images recorded
on an Alpha Image 90 documentation system (Alpha Inno-
tech, San Leandro, CA).
2.4. TUNEL Assay. TUNEL staining was performed using
the APO-BrdU TUNEL Assay kit from Molecular Probes
(Invitrogen, Eugene, OR). Brieﬂy, cells were washed and
ﬁxed in 1% paraformaldehyde and let stand overnight in
ice-cold ethanol at −20◦C. After two repeats of pelleting,
aspirating supernatant, and washing, cells were incubated in
a DNA-labeling solution for 60 minutes at 37◦C. At the end
of the incubation time, cells were rinsed and pelleted twice
after which they were incubated with the antibody staining
solution containing Alexa Fluor 488 dye-labeled anti-BrdU
antibodyfor30minandthendepositedonslidesandimaged
using the LSM 5-LIVE High Speed Confocal housed in
Delaware Biotechnology Institute, Newark, DE.
2.5. Statistical Analysis. All experiments were performed a
minimum of three separate times with individual transfec-
tions or treatments and performed with no less than three
replicates per experiment. Statistical analysis of the com-
bined experiments was performed using GraphPad Prism.
Signiﬁcance was deﬁned as a P value ≤0.001. Data is re-
presented as mean ± standard deviation.Bone Marrow Research 3
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Figure 1: Immunoﬂuorescence of markers associated with breast cancer stem cells. MCF-7 were treated with 25μMF T If o r7 2h ,ﬁ x e dw i t h
paraformaldehyde, and incubated with antibodies speciﬁc for CD44 or ALDH1. Shown is a comparison of dormant and growing MCF-7
cells.
3. Results
3.1. FTI-Responsive MCF-7 Cells Express Stem Cell Markers.
Previously, we demonstrated that a signiﬁcant number of
MCF-7 cells entered into a dormant phenotype when treated
with 25μM of the farnesyl transferase inhibitor (FTI) L-
744,832 [10]. To determine whether the dormant breast can-
cer cells expressed known breast cancer stem cell markers we
performedimmunoﬂuorescenceforaldehydedehydrogenase
1 (ALDH1) and cluster of diﬀerentiation 44 (CD44) on
FTI-treated MCF-7 cells (Figure 1). As described previously,
FTI treatment induced a ﬂattened and spread morphology
associated with dormancy in a large number of MCF-7 cells.
Cells that displayed the dormant morphology stained pos-
itive for ALDH1 and CD44. In contrast, growing MCF-7
cells did not stain for these described breast cancer stem cell
markers. These data suggest that MCF-7 cells susceptible to
FTI-induced dormancy may have stem-like properties.
3.2. FTI-Responsive Cells Express Early Markers of Autophagy.
Cells treated with FTI can remain in a dormant state for
nearly two weeks and maintain viability [10, 11]. It has been
suggested that dormant cancer cells undergo autophagy to
remain viable [16, 18]. Next, we queried whether FTI treat-
ment induced autophagy in these cells to promote cell sur-
vival under normal growth conditions. Figure 2(a) is western
blot analysis for the autophagy markers beclin, Atg5, Atg7,
Atg3, Atg12, and LC3B expressed by vehicle control and FTI-
treated MCF-7 cells. After 24 h FTI treatment, cells began to
display early changes in the protein expression of autophagy
markers indicative of autophagy. Interestingly, we observed
a loss of beclin expression when the cells were treated with
FTI.We did not detect Atg7 or Atg3 in untreatedor after24h
F T It r e a t m e n t .H o w e v e r ,d e t e c t a b l el e v e l so ft h eA t g 1 2a n d
Atg5 conjugate were observed in the FTI-treated cells. LC3B-
I is typically expressed in cells and its cleavage to LC3B-II
is indicative of autophagy. In our cells we did not observe
expression of LC3B-I or -II in growing (-FTI) MCF-7 cells.
Expression of LC3B-I and LC3B-II was detected when the
cells were treated with FTI.
We next used a pharmacologic inhibitor of auto-
phagy; 3-methyladenine (3-MA) is a speciﬁc inhibitor of4 Bone Marrow Research
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Figure 2:ExpressionofautophagymarkersinFTI-treatedcells.(a)SubconﬂuentMCF-7cellsweretreatedwith25μMFTIorvehiclecontrol
for 24h, cell lysates harvested and western blot analysis performed with antibodies for autophagy-associated proteins. (b) MCF-7 cells were
treated with FTI for 48h and then 5mM 3-MA or vehicle control added to the cultures. Cells were ﬁxed 24h later and a TUNEL assay
performed. The arrow represents a single positive apoptotic cell.
the autophagic/lysosomal pathway. Figure 2(b) is a compar-
ison of FTI-treated MCF-7 cells with and without the addi-
tion of 3-MA. Co-treatment of 3-MA and FTI led to a sig-
niﬁcant decrease in cells displaying a dormant phenotype. As
we previously demonstrated, dormant cells are signiﬁcantly
larger and spread out compared to nondormant, growing
cells [10]. We observed that the 3-MA treated cells reverted
from a large, spread morphology to a normal morphology.
Further, we expected that inhibition of autophagy with 3-
MA would signiﬁcantly increase apoptosis in the FTI-treated
cells. Using a TUNEL assay we found that very few cells were
undergoing apoptosis upon 3-MA treatment. Together, these
data suggest that induction of autophagy helps maintain the
FTI-induced dormant phenotype but that inhibition of the
autophagic/lysosomal pathway does not lead to increased
apoptosis, at least in the early stages of autophagy.
3.3. RhoC GTPase Is Required for FTI-Induced Dormancy.
RhoC GTPase expression and activation is suggested to
inﬂuence the breast cancer stem cell phenotype [22, 28].
Additionally, we have demonstrated that RhoC hyperac-
tivation drives breast cancer cell dormancy, potentially
through JNK/SAPK [10]. To determine if RhoC activation
drives the dormant phenotype by induction of JNK/SAPK
signaling and autophagy, we modulated RhoC activation in
control and FTI-treated cells. MCF-7 cells were transfected
with either a dominant active (G14V) or negative (T19N)
RhoC GTPase, treated with FTI and the levels of active
JNK/SAPK determined. Figure 3(a) is western blot analysis
of phosphorylated and total JNK/SAPK. Control cells were
transfected with empty vector. In comparison with the
control cells, active JNK/SAPK levels in RhoCG14V were
increasedregardlessofFTItreatment.Asigniﬁcantdiﬀerence
was particularly noted when the vehicle control treated
RhoCG14V transfected cells were compared to the vehicle-
treated empty vector control cells. In contrast, expression
of a dominant negative RhoC led to a signiﬁcant decrease
in phospho-JNK/SAPK levels in vehicle and FTI-treated
cells.SigniﬁcancewasdeterminedbetweenthevectorcontrolBone Marrow Research 5
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Figure 3:EﬀectofRhoCGTPaseonJNK/SAPKactivation.(a)MCF-7cellsweretransientlytransfectedwithemptyvector(ctrl),adominant
active (G14V), or dominant negative (T19N) RhoC GTPase, treated with 25μM FTI or vehicle control and levels of active and total
JNK/SAPK measured by western blot analysis. Shown is a representative western blot. Densitometry was performed using ImageJ and results
of the ratio of active: total JNK represented as arbitrary units (AU). For signiﬁcance
∗P ≤ 0.001. (b) representative western blot analysis of
LC3B-I/-II levels in FTI-treated cells after inhibition of JNK/SAPK with 25μM SP600125.
and RhoCT19N transfected cells treated with FTI. These
data suggest that RhoC activity aﬀects JNK/SAPK activation
through RhoC GTPase activation. Further, RhoC activation
via FTI-treatment leads to increased JNK/SAPK activity.
Next, we set out to determine if JNK/SAPK activity re-
gulates FTI-induced autophagy in MCF-7 cells. Cells were
pretreated with the JNK/SAPK inhibitor SP600125 and then
incubated with FTI. Figure 3(b) is western blot analysis dem-
onstrating that FTI-stimulated JNK/SAPK activation is in-
hibited with SP600125 pretreatment. Next, we assessed ex-
pression of the autophagy marker LC3B JNK/SAPK inhibi-
tion. SP600125 inhibition of FTI-induced JNK/SAPK signal-
ing prevented LC3B-I/-II expression in FTI-treated MCF-7
cells, suggesting JNK/SAPK activation leads to induction of
autophagy.
4. Discussion
A great deal of hope and eﬀort has been put into the
development of farnesyl transferase inhibitors, however they
have proven to be clinically disappointing. Attention has
been focused on the Rho GTPases as potential targets for
FTIs [29–34]. Evidence from our laboratory and others sug-
gested that inﬂammatory breast cancer (IBC) patients may
beneﬁt from FTI treatment [11] and reviewed in [35]. The
unique invasive IBC phenotype is due to expression of high
levels of RhoC GTPase [36–38]. The RhoC-driven invasive
IBC phenotype is inhibited by FTI treatment [11]. However,
we found that these FTI-treated IBC cells were resistant to
cell death and morphologically resembled what has been
described for an in vitro model of breast cancer cell dor-
mancy. Recently, we demonstrated that cells with low me-
tastatic potential were susceptible to FTI-induced dormancy
[10].
Tumor cell dormancy is a major clinical concern. Years
or even decades after a breast cancer patient is deemed
“cured”, highly aggressive recurrences can arise [21]. Very
little is known about the molecular basis of dormancy. It
is known that single cells can lie dormant in bone marrow.
Alternatively, small groups of cells lacking a proper blood
supply can lie dormant in the parenchyma of visceral organs.
The mechanisms of what keep these cells dormant or what
releasesthemarecurrentlyunknownandareanareaoffocus.
Markers such as ALDH1 and CD44 are shown to be
expressed by a subpopulation of cells in both tumors and
cells lines [23, 24, 39]. It is suggested that breast cancer cells
with stem cell properties are responsible for metastatic
spread [21, 40]. Further, RhoC GTPase is suggested to be6 Bone Marrow Research
expressed by highly metastatic cells that exhibit “stemness”
[22, 28]. Cancer stem cells have also been linked to dor-
mancy. It is thought that a metastatic stem cell arriving in a
nonconducive environment undergoes prolonged dormancy
[21]. This, in part, would explain why recurrences from dor-
mant cells can be so aggressive.
In the current study we demonstrate that cells under-
going dormancy after FTI treatment, express ALDH1 and
CD44. In contrast to breast cancer cell lines with greater
metastatic capabilities such as MDA-MB-231, the majority
of MCF-7 cells are susceptible to FTI-treatment and become
dormant [10]. This may be because the MCF-7 breast cancer
cell line has a large population of cells which have stem cell-
like properties and express ALDH1 and CD44 [26, 27].
Dormant cells are also thought to undergo autophagy
in order to survive [16–18]. Here we demonstrate that FTI-
treated cells express early markers of autophagy as com-
pared to controls. Pharmacologic inhibition of the autoph-
agic/lysosomal pathway leads to a reversion of the FTI-
induced dormant phenotype. Interestingly, it does not lead
to apoptosis of the FTI-treated cells. Evidence from Liu et
al. suggests an additional stress such as serum deprivation or
inhibitionofAkt1maybeneededtoinduceapoptosisinFTI-
treated MCF-7 cells [33, 41].
Induction of autophagy is linked to the JNK/SAPK path-
way [20, 42, 43]. Previously, we demonstrated that FTI-
treated cells exhibited drastic alterations in RhoA and RhoC
GTPase activation [10]. Speciﬁcally, RhoA became hypoac-
tivated while RhoC became hyperactivated. Hyperactivation
of RhoC was tied to increased JNK/SAPK activation and
dormancy. We demonstrate that JNK/SAPK activation is in-
creased when a dominant active RhoC is introduced into the
cells.ThelevelsofJNK/SAPKactivationaresimilartocontrol
cellstreatedwithFTIandcanbeabrogatedbyexpressionofa
dominantnegativeRhoC.DirectinhibitionoftheJNK/SAPK
pathway also leads to reversion of the dormant phenotype
(data not shown) and inhibition of the autophagic marker
LC3B-I/-II.
Together these data suggest that cells expressing the stem
cell markers ALDH1 and CD44 are susceptible to FTI-in-
duced dormancy. This phenotype is due to JNK/SAPK sig-
naling resulting from increased RhoC activation. In turn
JNK/SAPK signaling leads to induction of autophagy allow-
ing the cells to remain inactive. These data may have im-
plications for the use of FTIs in the clinic, limiting to tumors
that have a particular gene proﬁle. Potentially, FTI-induced
dormancy could synchronize tumor cells; FTI withdrawal
would allow growth making the cells more susceptible to
chemotherapeutics. In addition, this study may shed light on
the mechanisms of breast cancer dormancy.
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